Trials / Completed
CompletedNCT01305538
Crossover Post-herpetic Neuralgia (PHN)
A Randomized, Multicenter, Double-blind, Placebo-controlled, Cross-over Study of the Efficacy and Safety of BMS-954561 in Patients With Post-herpetic Neuralgia (PHN)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the efficacy of study drug (BMS-954561) as compared to placebo in the treatment of patients with post-herpetic neuralgia (PHN).
Detailed description
Allocation: Randomized Stratified Interventional model: Cross-over Placebo Controlled
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-954561 | |
| DRUG | BMS-954561 | |
| DRUG | Placebo |
Timeline
- Start date
- 2011-03-01
- Primary completion
- 2012-02-01
- Completion
- 2012-06-01
- First posted
- 2011-02-28
- Last updated
- 2015-12-07
Locations
23 sites across 2 countries: United States, France
Source: ClinicalTrials.gov record NCT01305538. Inclusion in this directory is not an endorsement.